A Global Consensus for Measuring Residual Disease in ALL: Key Recommendations from the 2026 Cross‑Age Guideline
An international expert panel issues unified recommendations to standardize measurable residual disease (MRD) testing in acute lymphoblastic leukemia across ages—covering samples, assays, nomenclature, monitoring, and MRD‑based remission and relapse definitions.
